Novo Nordisk chief executive Lars Fruergaard Jørgensen faced questioning on Capitol Hill over the health care costs of the company’s weight-loss drugs Ozempic and Wegovy. NBC News’ Christine Romans reports on how Jørgensen claimed the high prices were due to complications of the U.S. healthcare system.
Novo Nordisk chief executive Lars Fruergaard Jørgensen faced questioning on Capitol Hill over the health care costs of the company’s weight-loss drugs Ozempic and Wegovy. NBC News’ Christine Romans reports on how Jørgensen claimed the high prices were due to complications of the U.S.
healthcare system. Sept. 24, 2024.
